INSTRUCTION

(information for professionals)

for medical use of the drug

GLEATSER

 

Registration number: LSR-007815/09-051009

Trade name: GLEATSER

MIN or grouping name: Choline alphosceratus

Dosage form: solution for intravenous and intramuscular injection

Composition

Active ingredient:

Choline alphosceratus hydrate (based on anhydrous substance) ............. 250 mg

Adjuvant:

Water for injections 1 ml ...........................................................................

 

Description: Colorless transparent liquid

Pharmacotherapeutic group: nootropics

Code ATX: N07AX02

Pharmacological properties

Pharmacodynamics

 

Nootropic agent. Central holinostimulyagor , which included 40.5% contained metabolically protected choline. Metabolic protection promotes the release of choline in the brain.

Provides phosphatidylcholine and acetylcholine synthesis in neuronal membranes , and improves blood flow and increases the metabolic processes in the central nervous system and activates the reticular formation. Increases blood flow to the linear velocity of the traumatic brain injury contributes to the normalization of spatio-temporal characteristics of spontaneous brain activity , regression of focal neurological symptoms and recovery of consciousness ; has a positive effect on cognitive and behavioral responses of patients with cerebrovascular diseases ( circulatory encephalopathy and residual effects of cerebrovascular accident ) .

Provides preventive and corrective effect on the pathogenetic factors involyutsionnogo psychoorganic syndrome alters neuronal membrane phospholipid composition and reduced cholinergic activity .

Stimulates a dose-dependent release of acetylcholine in physiological conditions ; participating in the synthesis of phosphatidylcholine ( phospholipid membrane ) enhances synaptic transmission , neuronal plasticity membrane receptor function .

Does not affect the reproductive cycle , not teratogenic and mutagenic. Pharmacokinetics

Absorption - 88%. Choline alphosceratus easily penetrates the blood-brain barrier.

Light appears mainly in the form of carbon dioxide ( 85 % ), and through the intestine and kidney (15 %).

 

Indications for use

  • Head injury with predominantly stem lesion level (acute phase),
  • Cerebrovascular insufficiency,
  • Psycho-organic syndrome on the background of degenerative diseases and involutional processes in the brain,
  • Multi-infarct dementia.

 

Contraindications

  • Pregnancy, breast feeding,
  • Hypersensitivity to the drug.
  • Age 18,
  • Hemorrhagic stroke (acute phase).

Dosing and Administration

Intramuscular or slow intravenous injection of 1000 mg / day for 15-20 days.

For intravenous administration the contents of one vial (4ml) was diluted in saline.

 

Side effect

Allergic reactions, nausea.

 

Overdose

Symptoms: nausea. Treatment: symptomatic.

 

Interaction with other drugs

Significant interactions with other drugs has not been established.

 

Form of

Solution for intravenous or intramuscular administration of 250 mg / ml in ampoules or neutral lighting glass 4 ml. 3 vials or ampoules 5 contour blister. One blisters along with instructions for medical use in the stack of cardboard.

 

Shelf life

5 years. Do not use beyond the expiration date.

 

Storage conditions

List B. In a dry, dark place at a temperature not exceeding 25 ° C. Keep out of reach of children.

 

Terms of supply of pharmacies

Prescription.

 

Manufacturer / organization receiving the claim

Ltd. "Altair"

142100 Moscow region., Podolsk, st. Komsomolskaya 1. Tel. / Fax (4967) 31-20-74

 

Marketing in Russia

LLC «ESKO PHARMA»

115093, Moscow, ul. Pavlovian, 6

Tel.: +7 (495) 980 95 15

TOP